trending Market Intelligence /marketintelligence/en/news-insights/trending/EyCDJ767BP7JQh3IthAUFg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Sihuan receives Chinese drug registration approval for liver disease injection

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Sihuan receives Chinese drug registration approval for liver disease injection

Sihuan Pharmaceutical Holdings Group Ltd. has received drug registration approval from the National Medicinal Products Administration of China for its compound amino acid injection, the Beijing-based company said March 18.

The 500-milliliter injection is intended to prevent and treat hepatic encephalopathy, a liver condition that results in loss of brain function due to a buildup of toxins in the blood. It can also provide intravenous nutrition for acute liver disease patients.

According to Sihuan Pharmaceutical, the injection improves consciousness, liver function and blood ammonia in patients.

The current trend in clinical liver disease treatment is to replace the existing ordinary balanced amino acid injection with a compound amino acid injection containing 20 types of amino acid, Sihuan said. In China, compound amino acid injection sales were approximately 449 million yuan in 2017.

Sihuan's drug is the only fourth-generation, high-branched chain amino acid injection of this kind, the company said.